Active Biotech AB Interim Report January – March 2013

Apr 25, 2013 08:30 (CEST)
Laquinimod
· first patient enrolled in CONCERTO, the third Phase III placebo-controlled study for the treatment of
relapsing-remitting multiple sclerosis
· data presented at AAN showed reduced disability progression for multiple sclerosis patients who commenced
early treatment with laquinimod compared with delayed treatment 
                 
Tasquinimod     
· the Phase III study is proceeding according to plan
                      
ANYARA    
· Phase II/III study in renal cell cancer concluded
· Results presented:
   – study did not achieve primary clinical endpoint
   – doubling of progression-free survival and overall survival in 25 percent of patients
   – planning of the continued clinical development ongoing

57-57 (paquinimod)            
· clinical trial in systemic sclerosis concluded, evaluation underway

ISI                
· focus on submission of patents

Other information
· Active Biotech raised SEK 270 M through a directed share issue to Investor

      Jan – Mar Jan – Dec
 (SEK M) 2013 2012 2012
  •      Net sales
   2.4    2.6 227.9
  •      Operating loss
  -77.0 -100.7 -163.2
  •      Net loss
 -78.0 -99.0 -175.0
  •      Earnings per share (SEK)
 -1.10 -1.44 -2.54

 

For further information, please contact:

Tomas Leanderson, President and CEO
Tel: +46 (0)46-19 20 95                                        
Hans Kolam, CFO                                                 
Tel: +46 (0)46-19 20 44                                                         

Active Biotech AB Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 
Lund
Tel: 046 (0)46-19 20 00 
Fax: +46 (0)46-19 11 00

This report is also available at www.activebiotech.com                       

Active Biotech AB : Interim Report January – March 2013

—
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: Active Biotech via Thomson Reuters ONE
HUG#1695994